NYSE American: IGC

Investor Relations

Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.

igc pharma
IGC Provides Corporate Updates
Read More →
SL-3-3 (2)
IGC to Re-list Securities on Alternative Exchange
Read More →
SL-3-3 (2)
NYSE American to Suspend Trading in India Globalization Capital and Commence Delisting Proceedings
Read More →
SL-3-3 (2)
IGC Announces Financial Results for Quarter Ended September 30, 2018
Read More →
SL-3-3 (2)
IGC Files Provisional Patent to Protect IP for CBD-Infused Energy Drink
Read More →
SL-3-3 (2)
IGC to Enter the Hemp/CBD-Infused Energy Drink Space
Read More →
SL-3-3 (2)
India Globalization Capital Raises $1 Million in Direct Equity Investment to Support Hyalolex Commercialization
Read More →
SL-3-3 (2)
IGC to Enter California Market with Hyalolex
Read More →
SL-3-3 (2)
IGC Announces Results of its 2018 Annual Stockholders Meeting
Read More →
SL-3-3 (2)
IGC Announces Financial Results for Quarter Ended June 30, 2018
Read More →
SL-3-3 (2)
IGC Announces … Drops of Clarity ‚  Marketing Initiatives for Hyalolex’ ¢Ã¢â‚¬Å¾Ã‚ ¢
Read More →
SL-3-3 (2)
IGC Announces Financial Results for Fiscal Year Ended March 31, 2018
Read More →
SL-3-3 (2)
IGC to Hold Annual Meeting of Stockholders on August 6, 2018
Read More →
SL-3-3 (2)
IGC Radica Patente para la F’ƒÂ ³rmula Hyalolex
Read More →
SL-3-3 (2)
IGC Files Patent for Hyalolex Formulation
Read More →
SL-3-3 (2)
IGC Partners to Launch Hyalolex in Puerto Rico
Read More →